These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 18640437)

  • 1. Will anti-amyloid therapies work for Alzheimer's disease?
    St George-Hyslop PH; Morris JC
    Lancet; 2008 Jul; 372(9634):180-2. PubMed ID: 18640437
    [No Abstract]   [Full Text] [Related]  

  • 2. Amyloid antibody therapy for early-stage Alzheimer's disease: a critical review of three recent trials.
    Guiloff AE; Rudge P
    J Neurol; 2024 May; 271(5):2914-2916. PubMed ID: 38613568
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA approves third anti-amyloid antibody for Alzheimer disease.
    Mullard A
    Nat Rev Drug Discov; 2024 Aug; 23(8):571. PubMed ID: 38969747
    [No Abstract]   [Full Text] [Related]  

  • 4. Measuring our language about anti-amyloid antibodies in Alzheimer's disease: Technical, theoretical, and lay language considerations.
    Daly T; Kurkinen M
    Clin Neurol Neurosurg; 2024 Jun; 241():108314. PubMed ID: 38703469
    [No Abstract]   [Full Text] [Related]  

  • 5. Monoclonal anti-amyloid antibodies for the treatment of Alzheimer's disease and the hesitant geriatrician.
    Chin NA; Widera E; Brangman SA; Karlawish J
    J Am Geriatr Soc; 2024 Feb; 72(2):643-645. PubMed ID: 37909226
    [No Abstract]   [Full Text] [Related]  

  • 6. Talking With Patients About the New Anti-amyloid Alzheimer Disease Medications.
    Sarkisian CA; Romanov A; Mafi JN
    Ann Intern Med; 2024 Feb; 177(2):246-248. PubMed ID: 38252943
    [No Abstract]   [Full Text] [Related]  

  • 7. Author Response: Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
    Vassilaki M; Pittock RR; Aakre JA; Castillo AM; Ramanan VK; Kremers WK; Jack CR; Vemuri P; Lowe VJ; Knopman DS; Petersen RC; Graff-Radford J
    Neurology; 2024 May; 102(9):e209377. PubMed ID: 38648608
    [No Abstract]   [Full Text] [Related]  

  • 8. Author Response: Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
    Vassilaki M; Graff-Radford J
    Neurology; 2024 Aug; 103(3):e209371. PubMed ID: 38968547
    [No Abstract]   [Full Text] [Related]  

  • 9. Reader Response: Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
    Chiabotti PS; Rouaud O; Allali G
    Neurology; 2024 May; 102(9):e209375. PubMed ID: 38648577
    [No Abstract]   [Full Text] [Related]  

  • 10. Reader Response: Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging.
    Connolly E; O'Connor A; Fallon A; O'Dowd S; Kennelly SP
    Neurology; 2024 Aug; 103(3):e209343. PubMed ID: 38968562
    [No Abstract]   [Full Text] [Related]  

  • 11. Ultrasound and antibodies - a potentially powerful combination for Alzheimer disease therapy.
    Götz J; Padmanabhan P
    Nat Rev Neurol; 2024 May; 20(5):257-258. PubMed ID: 38378999
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.
    Holmes C; Boche D; Wilkinson D; Yadegarfar G; Hopkins V; Bayer A; Jones RW; Bullock R; Love S; Neal JW; Zotova E; Nicoll JA
    Lancet; 2008 Jul; 372(9634):216-23. PubMed ID: 18640458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PCSK9 acts as a key regulator of Aβ clearance across the blood-brain barrier.
    Mazura AD; Ohler A; Storck SE; Kurtyka M; Scharfenberg F; Weggen S; Becker-Pauly C; Pietrzik CU
    Cell Mol Life Sci; 2022 Mar; 79(4):212. PubMed ID: 35344086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The NLRP3 inflammasome modulates tau pathology and neurodegeneration in a tauopathy model.
    Stancu IC; Lodder C; Botella Lucena P; Vanherle S; Gutiérrez de Ravé M; Terwel D; Bottelbergs A; Dewachter I
    Glia; 2022 Jun; 70(6):1117-1132. PubMed ID: 35174546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of escitalopram on Aβ levels and plaque load in an Alzheimer mouse model.
    Cirrito JR; Wallace CE; Yan P; Davis TA; Gardiner WD; Doherty BM; King D; Yuede CM; Lee JM; Sheline YI
    Neurology; 2020 Nov; 95(19):e2666-e2674. PubMed ID: 32913022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroimaging of Alzheimer's disease: focus on amyloid and tau PET.
    Matsuda H; Shigemoto Y; Sato N
    Jpn J Radiol; 2019 Nov; 37(11):735-749. PubMed ID: 31493197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How the formation of amyloid plaques and neurofibrillary tangles may be related: a mathematical modelling study.
    Kuznetsov IA; Kuznetsov AV
    Proc Math Phys Eng Sci; 2018 Feb; 474(2210):20170777. PubMed ID: 29507520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nucleic Acid-Based Theranostics for Tackling Alzheimer's Disease.
    Chakravarthy M; Chen S; Dodd PR; Veedu RN
    Theranostics; 2017; 7(16):3933-3947. PubMed ID: 29109789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and future implications of basic and translational research on amyloid-β peptide production and removal pathways.
    Bohm C; Chen F; Sevalle J; Qamar S; Dodd R; Li Y; Schmitt-Ulms G; Fraser PE; St George-Hyslop PH
    Mol Cell Neurosci; 2015 May; 66(Pt A):3-11. PubMed ID: 25748120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Models of β-amyloid induced Tau-pathology: the long and "folded" road to understand the mechanism.
    Stancu IC; Vasconcelos B; Terwel D; Dewachter I
    Mol Neurodegener; 2014 Nov; 9():51. PubMed ID: 25407337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.